This clinical trial is a randomized, double-blind, placebo-controlled, single ascending dose, phase 1 clinical trial to evaluate the safety/tolerability and pharmacokinetic characteristics, and to explore food effect and ethnic difference of JW2286 after oral administration in healthy adults.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Enrollment
72
a single administration of JW2286 per dose
a single administration of Placebo of JW2286 per dose
Seoul National University Hospital Clinical Trial Center
Seoul, South Korea
RECRUITINGArea under the plasma drug concentration-time curve from 0 to last (AUClast) of JW2286
Pharmacokinetic Characteristics Evaluation
Time frame: 0 to 168 hours
Area under the plasma drug concentration-time curve from 0 to infinity (AUCinf) of JW2286
Pharmacokinetic Characteristics Evaluation
Time frame: 0 to 168 hours
The maximum or peak concentration between zero and dosing interval (Cmax) of JW2286
Pharmacokinetic Characteristics Evaluation
Time frame: 0 to 168 hours
Time of Maximum Concentration (Tmax) of JW2286
Pharmacokinetic Characteristics Evaluation
Time frame: 0 to 168 hours
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.